Moneycontrol Be a Pro
Get App
you are here: HomeNewsBusiness
Last Updated : May 21, 2019 11:24 AM IST | Source: PTI

Alembic Pharma gets USFDA nod for overactive bladder treatment drug

The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Solifenacin Succinate tablets in the strengths of 5 mg and 10 mg, Alembic Pharmaceuticals said in a BSE filing.

Representative image
Representative image
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Alembic Pharmaceuticals on Tuesday said it has received approval from the US health regulator for Solifenacin Succinate tablets, used for treatment of overactive bladder. The approved products is therapeutically equivalent to the reference listed drug, Vesicare tablets of Astellas Pharma US, Inc.

The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Solifenacin Succinate tablets in the strengths of 5 mg and 10 mg, Alembic Pharmaceuticals said in a BSE filing.

Quoting IQVIA sales data, the company said, Solifenacin Succinate tablets 5 mg and 10 mg had an estimated market size of USD 967 million for 12 months, ending December 2018.

Close

The company said it now has a total of 94 ANDA approvals from the USFDA.

Shares of Alembic Pharmaceuticals were trading at Rs 533.40 apiece, up 0.77 per cent, on the BSE.

The Great Diwali Discount!
Unlock 75% more savings this festive season. Get Moneycontrol Pro for a year for Rs 289 only.
Coupon code: DIWALI. Offer valid till 10th November, 2019 .
First Published on May 21, 2019 11:15 am
Loading...
Sections
Follow us on
Available On